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Randomized comparison of ePTFE/nitinol self-
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bypass in the treatment of superficial femoral artery
occlusive disease
Karen McQuade, MD,a Dennis Gable, MD,a Stephen Hohman, MD,a Greg Pearl, MD,a and
Brian Theune, MD,b Dallas, Tex; and Fort Bragg, NC
Background: A randomized prospective study comparing the treatment of superficial femoral artery occlusive disease
percutaneously with an expanded polytetrafluoroethylene (ePTFE)/nitinol self-expanding stent graft (stent-graft) vs
surgical femoral to above knee popliteal artery bypass with synthetic graft material.
Methods: One hundred limbs in 86 patients with superficial femoral artery occlusive disease were evaluated from March
2004 to May 2005. Patient symptoms included both claudication and limb threatening ischemia with or without tissue
loss. The TransAtlantic InterSociety Consensus (TASC) II A (N 18), B (N 56), C (N 11), and D (N 15) lesions
were included. Patients were randomized prospectively into one of two treatment groups; a percutaneous treatment
group (group A; N  50) with angioplasty and placement of one or more stent-grafts or a surgical treatment group
(group B; N 50) with a femoral to above knee popliteal artery bypass using synthetic conduit (Dacron graft or ePTFE).
Patients were followed for a total of 24 months. Follow-up evaluation included clinical assessment and physical
examination, ankle-brachial indices (ABI), and color flow duplex sonography at 3, 6, 9, 12, 18, and 24 months.
Results: The mean total lesion length of the treated arterial segment in the stent-graft group was 25.6 cm (SD  15 cm).
The stent-graft group demonstrated a primary patency of 81%, 72%, and 63% with a secondary patency of 86%, 83%, and
74% at 6, 12, and 24 months, respectively. The surgical femoral-popliteal group demonstrated a primary patency of 84%,
77%, and 64% with a secondary patency of 89%, 86%, and 76% at 6, 12, and 24 months, respectively. No statistical
difference was found between the two groups with respect to primary (P  .716) or secondary patency (P  .695).
Grouping of less severe (TASC II A/B) vs more severe (TASC II C/D) lesions demonstrated patency at 24 months for
the femoral-popliteal arm of 63% and 67%, respectively while that of the stent-graft arm was 64% and 47%, respectively.
Secondary patency was 76% in both TASC classifications for the femoral-popliteal arm with 78% and 47% patency found
respectively in the stent-graft group. These resulted in no significant difference for primary (P  .978) or secondary
(P  .653) patency overall, although there is a trend for decreased patency with higher TASC II lesions.
Conclusion: Management of superficial femoral artery occlusive disease with percutaneous stent-grafts exhibits similar primary
patency at 24-month follow-upwhen comparedwith conventional femoral-popliteal artery bypass graftingwith synthetic conduit.
This treatment method may offer an alternative to treatment of the superficial femoral artery segment for revascularization when
prosthetic bypass is being considered or when autologous conduit is unavailable. (J Vasc Surg 2009;49:109-16.)The superficial femoral artery (SFA) is a common loca-
tion for the origination of symptomatic lower extremity
vascular disease. Advances in endovascular therapy have
provided new options for treatment of disease in this arte-
rial segment. Lesions previously thought amenable only to
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percutaneously. In an early international trial study group,
Lammer et al1 deployed the Hemobahn endoprosthesis
(W. L. Gore and Associates, Inc, Flagstaff, Ariz) in 80 limbs
with occlusive femoral-popliteal lesions. A primary patency
of 90% and 79%, at 6- and 12-month follow-up, respec-
tively, was achieved. Subsequent to this report, the graft
delivery system was modified (although the graft itself
remained without change) and was renamed the Viabahn
endoprosthesis. Ensuing studies of this stent- graft plat-
form in the SFA have demonstrated similar results.2-13 We
have previously published a midterm report on the current
series with a 12-month follow-up demonstrating primary
and secondary patency rates of 74% and 84% respectively in
both a stent-graft arm (n  50) and surgical arm (n 
50).14 While vein bypass is still considered the “gold stan-
dard” in surgical treatment of severe atherosclerotic dis-
ease, synthetic graft is often used in current practice for
femoral-popliteal above knee bypass for various reasons
including lack of acceptable venous conduit or for patients
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study was to compare the efficacy of the stent graft vs open
surgical femoral to above-knee popliteal bypass in the treat-
ment of SFA occlusive disease.
MATERIALS AND METHODS
Study design. Our study design has been previously
published.14 Briefly, the study is a prospective, randomized
trial carried out at a single institution between March 2004
and May 2005. The study was approved by the FDA with
an investigational device exemption (IDE) and was ap-
proved and monitored by the hospital institutional review
board. All study participants signed an informed consent
agreement as part of the initial enrollment. Patients with
symptoms of lifestyle-altering claudication or rest pain with
or without tissue loss were evaluated for treatment. Clinical
examination and noninvasive studies (ankle-brachial indi-
ces and color-flow duplex ultrasonography) were used to
confirm infrainguinal disease. All patients considered for
treatment subsequently underwent digital subtraction an-
giography or computed tomography angiography to eval-
uate the location and extent of atherosclerotic disease.
Inclusion criteria consisted of patients that had athero-
sclerotic stenotic or occlusive lesions of the superficial fem-
oral artery with no significant aorto-iliac disease. The infr-
apopliteal segment had to be patent with at least single
vessel run-off to the ankle. Patients had to be acceptable
surgical candidates in the event they were randomized to
the surgical arm.
Enrolled patients were prospectively randomized by
limb prior to intervention into one of two treatment
groups: percutaneous endovascular treatment with the
stent-graft or open surgical femoral to above-knee popliteal
artery bypass with synthetic graft.
Study population. Between March 2004 and May
2005, a total of 100 limbs in 86 patients met the inclusion
criteria as described. Forty patients (50 limbs) were ran-
domized to treatment with the stent-graft and 46 patients
(50 limbs) were randomized to treatment with femoral to
above-knee popliteal artery bypass. The demographic data
and associated comorbidities are summarized in Table I.
While there was a statistical difference in patient age be-
tween the two treatment groups, there was no significant
difference found in the patient comorbidities.
Technique. Stent graft design with our open surgical
and endovascular technique have been previously pub-
lished.14 Briefly, all patients were accessed percutaneously
in the common femoral artery via standard Seldinger tech-
nique and were fully anticoagulated with heparin (100
units/kg). Subintimal dissection was used to cross occlu-
sive lesions with predilatation angioplasty of the lesion to be
treated then being performed. Lesion length was recorded
by in-plane technique using a marking catheter. Stent-graft
deployment was accomplished with stents being sized to
vessel diameter. Post deployment angioplasty molding was
then performed. After stent-graft placement, patients were
immediately started on aspirin (81-325 mg/d) and clopi-
dogrel (75 mg/d) for a minimum of 3 months. Patientsreceiving warfarin therapy for other associated conditions
prior to treatment were continued on the drug in addition
to aspirin 81 mg/d. Clopidogrel was not used in these
cases. After 3 months of treatment, antiplatelet therapy was
left to the discretion of the treating physician. The choice of
surgical conduit was also left to the discretion of the oper-
ating surgeon and was either ePTFE or Dacron graft. An
identical antiplatelet regimen as previously described was
instituted postoperatively for the surgical arm.
Postoperative assessment and follow-up examination.
After discharge, follow-up included clinical examination,
color flow Doppler ultrasound, and ankle-brachial indices
at 3, 6, 9, 12, 18, and 24 months. Color flow Doppler
ultrasound was performed at an approved ICAVL labora-
tory and used to assess patency of grafts and to detect
recurrent arterial or graft stenosis. Primary and secondary
patency rates and graft failure rates were defined with the
criteria previously described by Ahn15 and Rutherford.16
Graft failure was defined as stent-graft/bypass thrombosis,
restenosis of50% of the treated arterial segment immedi-
ately above or below the stent-graft/bypass graft (anasta-
motic or stent landing zone sites), intra-stent/intra-graft
restenosis 50%, or a decrease in the ankle-brachial index
of 0.15 or greater.
Statistical analysis. An independent statistician re-
viewed all submitted data and performed the correspond-
ing statistical calculations. The Kaplan-Meier method was
used to calculate primary and secondary patency rates vs
time of follow-up. The log-rank test was used to determine
the statistical difference in patency rates and amputation
rates between the two treatment groups. A two-tailed t test
with pooled variances and two-tailed Fisher exact test was
used to evaluate differences in patient demographics. The
Fisher exact test (generalized version for tables beyond 2
2) was used to evaluate differences in grades of chronic limb
ischemia pretreatment and in TransAtlantic InterSociety
Consensus (TASC) II classification. A two-tailed t test was
used when determining statistical significance for improve-
ment of ankle-brachial indices and to evaluate cost compari-
Table I. Patient demographics
Stent-graft
group
(N  40)
Surgical bypass
group
(N  46)
P
value
Mean age 72 (SD  9.9;
range 40-84)
67 (SD  10.7;
range 40-86)
.0333a
Smoking history 22 27 .8280b
Diabetes 14 20 .5090b
CAD 13 22 .1886b
HTN 30 42 .0763b
Hyperlipidemia 23 21 .2862b
COPD 2 8 .0973b
CAD, Coronary artery disease; HTN, hypertension; COPD, chronic ob-
structive pulmonary disease.
Four patients randomized one limb to both treatment groups.
aTwo-tailed t test with pooled variances.
bTwo-tailed Fisher exact test.son data. A P value .05 was considered statistically signifi-
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patients in each arm, significance set at P  .05, and the
assumption that mean patencies are within 23% gives a study
power of 80%. The purpose of the study was explorative to
show the similarity of the mean estimates and confidence
intervals for the treatments along with the P value.
RESULTS
Between March 2004 and May 2005, 50 limbs in 40
patients were treated percutaneously with the stent-graft
and 50 limbs in 46 patients were treated surgically with
femoral to above-knee popliteal artery bypass. Pretreat-
ment clinical categories of chronic limb ischemia using
Rutherford’s classification16 of pretreatment limb ischemia
are shown in Table II. No significant difference in pretreat-
ment clinical grades between the two treatment groups was
noted. By following the TASC II grading system17 for
femoral-popliteal lesions, each limb in both treatment
groups was assigned a TASC II classification as shown in
Table III. There was not a significant difference in TASC II
classification between the two treatment groups.
Stent-graft placement was technically successful in
100% of limbs in the stent-graft group. A total of 114
devices were implanted in 50 limbs with a mean of 2.3
stent-grafts placed per limb. Mean diameter of the stent-
grafts was 5.7 mm (range; 5-7 mm). Mean total length of
artery covered with the stent-graft was 25.6 cm (SD 15
cm). Posttreatment, 37 (93%) of 40 patients in the stent-
graft group took clopidogrel and aspirin for a minimum of
3 months. One patient claimed an allergy to clopidogrel
while two other patients refused to take clopidogrel. These
Table II. Pretreatment distribution of chronic limb
ischemia categories (Rutherford16)
Clinical grade
Stent-graft limbs
N  50
Surgical bypass limbs
N  50
0 0 0
1 2 1
2 23 20
3 16 10
4 4 10
5 4 7
6 1 2
Generalized Fisher exact test, P  .3676.
Table III. Lesion TASC II classification per limb17
TASC
Surgical bypass
N  50
Stent-graft
N  50
A 8 10
B 27 29
C 5 6
D 10 5
TASC, TransAtlantic InterSociety Consensus.
Generalized Fisher exact test, P  .5829.three patients did take aspirin.Femoral to above knee popliteal artery bypass was
successfully performed in 100% of limbs in the surgical
group. Dacron grafts were used in 32 limbs (64%) and
ePTFE was used in 18 limbs (36%). Mean diameter of the
synthetic bypass grafts was 7.4 mm (range; 7-8 mm).
Twenty-four of 46 patients (52%) were on clopidogrel and
aspirin posttreatment for a minimum of 3 months. Seven-
teen patients were on aspirin only based on the recommen-
dation of the treating surgeon. The remaining five patients
were on warfarin preoperatively and were continued on this
regimen postoperatively.
Immediate procedure related and early postoperative,
nonthrombotic complications are outlined in our previous
series.14 Complications were noted in four of 40 patients
(50 limbs; 8%) treated with the stent-graft. These included
an SFA dissection (n  1), transient mild leg edema (n 
1), transient thigh pain in the treated limb (n 1), and one
patient with a small groin hematoma. In the surgical bypass
group, early postoperative complications were observed in
three of 46 patients (50 limbs; 6%). These three patients
developed a groin lymphocele (n 2; one requiring explo-
ration and drainage) and a small superficial groin wound
dehiscence (n  1).
Length of hospital stay was analyzed for both groups.
The mean hospital stay for the stent-graft group was found
to be 0.9 days (SD  0.8 days) and the mean stay for the
surgical group was found to be 3.1 days (SD  1.8 days).
This difference proved to be significant (P  .001; t test).
Complete 24-month follow-up for all patients was
available for 39 (78%) of 50 limbs in the stent-graft group.
Six patients expired during the study period from condi-
tions unrelated to infrainguinal disease (one with bilateral
limbs enrolled), and all but one of these patients had tissue
loss preoperatively. Four patients were lost to follow-up.
During follow-up, a total of 17 of the stent-grafts failed
secondary to thrombosis. Early graft thrombosis occurred
in the recovery room the same day of the procedure in one
patient. One stent-graft thrombosis occurred within the
first month after stent-graft implantation. The other 15
stent-graft thromboses were detected after a mean period
of 8.2 months (SD  6 months) after placement. None of
the three patients in the stent-graft group that were not on
clopidogrel posttreatment developed a thrombosed stent-
graft. Among the 17 thrombosed stent-grafts, 11 were
TASC II B lesions. Of the remaining six thrombosed grafts,
there were two each of TASC II A, C, and D lesions.
Of the 17 grafts that thrombosed, five (29%) under-
went successful open mechanical balloon thrombectomy.
One of the 17 was successfully recanalized with intra-
arterial mediated lysis. In 10 of the 17 cases (59%), attempts
at thrombectomy or lysis were unsuccessful, and these
patients eventually underwent open surgical bypass (six to
the above knee popliteal artery; four to tibial vessels).
Finally, one of the patients with a thrombosed stent-graft
was found to have heparin induced thrombocytopenia and
amputation eventually was performed due to progressive
tissue loss. This patient had tissue loss preoperatively. Over-
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treatment group during 24 months.
Complete 24-month follow-up was available for 40
of 50 limbs (80%) in the surgical bypass group. Five
patients expired due to conditions unrelated to their
infrainguinal disease. Five patients were lost to follow-
up. There were 14 incidences of synthetic graft throm-
bosis and one anastomotic stenosis greater than 50%
accounting for a total of 15 graft failures. Of the 14
thrombosed grafts, 10 were TASC II B lesions and four
were TASC II D lesions. None were TASC II A or C
lesions. One graft thrombosis occurred within the first
month after implantation. The other 13 were detected
after a mean of 10.8 months (SD  7.2 months). Five of
the 14 thrombosed synthetic grafts were successfully
de-clotted with mechanical balloon thrombectomy.
Three patients underwent below knee popliteal artery
bypass with great saphenous vein after thrombectomy
failed. Two patients underwent a redo femoral above
knee popliteal bypass with venous conduit. One patient
with a proximal anastomotic stenosis greater than 50%
was observed without intervention, and one patient with
a graft thrombosis remained with a viable limb without
further intervention being required. In three instances,
ischemia from clotted grafts eventually led to below-
knee amputation. In two cases, progressive tissue loss
despite patent grafts led to two additional amputations.
All instances of limb amputation occurred in patients
that had tissue loss preoperatively. Overall, 17 interven-
tions had to be performed in the surgical bypass group
during 24 months.
Cumulative primary and secondary patency rates were
calculated with use of the Kaplan-Meier method. The pri-
mary patency rate for the stent-graft group at 6, 12, and 24
months was 81%, 72%, and 63%, respectively, while the
primary patency for the surgical bypass group was 84%,
77%, and 64%, respectively (Table IV, online only). Sec-
ondary patency at 6, 12, and 24 months was 86%, 83%, and
74% for the stent-graft group and 89%, 86%, and 76% for
the surgical arm, respectively (Table V, online only). There
was no significant difference in primary patency (P .716)
or secondary patency (P  .695) between the two treat-
ment groups. All limbs in the stent-graft treatment group
(100%) and 46 limbs in the surgical bypass group (92%)
experienced an initial improvement in the Rutherford clas-
sification grade.16 The overall initial immediate postinter-
vention mean improvement was 2.4 clinical grades in both
treatment arms (P  .109; Fisher exact test). This was
maintained at 24 months (for all primarily patent limbs)
with a mean improvement of 2.4 clinical grades for the
stent-graft group and 2.5 clinical grades for the surgical
group (P  .095; Fisher exact test).
If grouped and evaluated independently by less severe
(TASC II A/B) vs more severe (TASC II C/D) lesions,
primary patency at 24months for the femoral-popliteal arm
was 63% and 67%, respectively, while that of the stent-graft
arm was 64% and 47%, respectively (Table VI, online only).
Secondary patency was 76% in both TASC II classificationgroups for the femoral-popliteal arm with 78% and 47%
patency found respectively in the stent-graft arm (Table
VII, online only). Although this resulted in no significant
difference for primary (P  .978) or secondary (P  .653)
patency overall when calculated, the patient numbers sep-
arated in this manner are far too small to perform any type
of meaningful statistical analysis. The lower patency in the
TASC II C/D lesions in the stent-graft arm are attributed
to starting with 11 patients in this cohort at the outset, five
patients that were censored during the treatment interval
and only four stent-graft thrombosis. This is borne out in
the wide confidence interval noted for the last 6 months of
follow-up in this subset. Nonetheless, the apparent trend
certainly cannot be overlooked for a lower patency with
treatment of higher TASC II lesions.
Limb salvage at 24-month follow-up was not signifi-
cantly different at 98% for the stent-graft patients and 89%
for surgical bypass patients (P  .081; Table VIII, online
only). Baseline ABIs for the stent-graft group and the
surgical bypass group were 0.57 (SD  0.19) and 0.46
(SD 0.22), respectively. At 12 months (for patients with
primarily patent limbs), the mean improvement in ABI for
the stent-graft group was 0.28 and for the surgical group
0.48 (P.042; two tailed t test). At 24 months, these were
measured at 0.23 in the stent-graft arm and 0.38 in the
surgical arm (P .143; two tailed t test).
Although this study was not originally designed or
statistically powered to evaluate cost comparison or patency
differences between different sized stent grafts and between
surgical grafts, several trends are noted. Retrospective cost
analysis was performed for both treatment groups. Costs
billed and collected by the hospital facility were obtained
retrospectively and mean values were calculated. Some data
was unavailable as the collection of this specific data was not
originally included in the study design. There is a significant
difference between the stent-graft group and surgical treat-
ment group in regards to facility costs as seen in Table IX
with the stent-graft cohort being a more costly treatment
method. The difference for facility reimbursement was felt
to be somewhat tempered by a higher reimbursement for
the stent-graft group in comparison with the surgical
group. If the stent-graft cohort is further broken down,
there was a trend towards higher reimbursement for inpa-
tient services as opposed to outpatient procedures for the
stent-graft cohort (Table X).
Evaluating the stent-graft group (Figs 1 and 2; Tables
XI and XII, online only), there is a trend towards improved
primary and secondary patency for device sizes of 6-7 mm
as compared with 5 mm although this trend is not statisti-
cally significant for primary (P  .356) or secondary pa-
tency rates (P  .670). The primary patency of the larger
stent graft sizes (6-7 mm) is better compared with surgical
bypass (69% vs 64%, respectively) and the secondary pa-
tency is similar also at 77% vs 76%, respectively. Again, this
difference is not significant (P .727; log-rank). Analyzing
the stent-graft cohort separately, the 5 mm devices have a
lower primary patency rate (54%), but they do approach a
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sizes and to femoral-popliteal bypass. Analysis of stent graft
patency by device size and TASC II classification does not
demonstrate any observed difference between the TASC II
classifications for primary or secondary patency as shown in
Tables XIII and XIV, online only, although, as previously
noted, there appears to be a possible trend for decreased
patency with higher TASC II C/D lesions.
DISCUSSION
The SFA is a common site of atherosclerotic plaque
formation in individuals with symptomatic lower extremity
Fig 1. Primary patency by stent-graft size versus surgical group.
Table IX. Cost analysis by treatment group
Stent-gra
Facility cost (US dollars)
n (data available) 39
Mean (std dev) $10,798.76 ($
Median $9626.9
Facility reimbursement (US dollars)
n (data available) 36
Mean (std dev) $ 9178.00 ($
Median $8609.5
aTwo-tailed t test.
Table X. Cost analysis of stent-graft patients by type of ad
In-patie
Facility cost (US dollars)
n (data available) 12
Mean (std dev) $11,854.43 ($5
Median $10,502.
Facility reimbursement (US dollars)
n (data available) 12
Mean (std dev) $10,227.33 ($2
Median $11,120.
aTwo-tailed t test.arterial occlusive disease. Traditional intervention for thisdisease required open arterial bypass with debate centered
on the choice of bypass conduit; autogenous vein (felt by
most to be the “gold standard”) vs synthetic graft. Numer-
ous reports have confirmed the long-term superiority in
patency of vein over synthetic conduit,18,19 however, many
physicians continue to use synthetic grafts particularly in
the above knee position for various reasons such as unavail-
ability of venous conduit or for patients considered to be
poor operative risks. Technological advances and matura-
tion of endovascular skills have allowed percutaneous treat-
ment of SFA occlusive disease to flourish, and many lesions
previously felt amenable only to open surgical bypass may
Fig 2. Secondary patency by stent-graft size versus surgical
group.
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neous transluminal angioplasty has proven to be effective in
short segment stenosis but has proved disappointing as a
primary treatment modality for longer segment disease and
total occlusions. A 3-year retrospective review of 104 pa-
tients (159 lesions) was published by Scott et al in 2007
demonstrating a 12-, 24-, and 36-month primary patency
of 55%, 43%, and 35%, respectively.20 The addition of
self-expanding bare metal nitinol stents has improved out-
comes slightly for short to moderate length arterial seg-
ments (4-12 cm), but also introduced the problems of
in-stent stenosis and stent fracture.21-23 The current study,
to our knowledge, is the only randomized prospective trial
that directly compares treatment of SFA occlusive disease in
both a surgical bypass arm and an endovascular arm. Our
initial technical success rate in both arms of 100% and our
primary and secondary patency rates in both arms mirrors
that of numerous previously published reports.2-13,18,19
Our initial report demonstrated a majority of stent-
graft patients as TASC C and D lesions, but reclassification
into the updated TASC II criteria dropped several of these
limbs to TASC II B lesions. Reclassification resulted in
approximately 60% of patients in both arms as TASC II B
and 25% to 30% as TASC II C or D lesions. Arterial
occlusions in the stent-graft cohort were seen within all
TASC II classifications. Over two thirds of all occlusions in
both groups were in the TASC II B classification corre-
sponding to the group with the highest number of patients
overall. Evaluating the treated limbs by TASC II classifica-
tion results in no observed difference in the TASC II lesion
being treated but does suggest a trend for decreased pa-
tency in higher TASC II lesions although the number of
patients per classification category is too small to draw any
significant conclusions in that regard. There remains con-
cern among many that acute failure and/or thrombosis of
the stent graft will result in a higher grade of ischemia at
presentation necessitating a more complex urgent surgical
revascularization and/or eventual higher rate of limb
loss.24 This concern was not validated in our study as we
found no statistical difference in limb loss between the two
treatment groups with only one amputation in 17 stent
graft failures. In addition, of those limbs requiring bypass
reconstruction in the stent-graft cohort, 60% were able to
be performed above the knee.
There is an observed trend towards decreased patency
in patient limbs treated with the 5 mm stent-grafts com-
pared with the 6 and 7 mm devices, although we found no
significant difference in patency through 24 months. If we
evaluate only the 6 and 7 mm stent-graft patients indepen-
dently vs the femoral-popliteal bypass patients, the primary
and secondary patency of the stent-graft patients is better
than those with the femoral-popliteal as previously shown.
A majority of patients treated by endovascular means
required only outpatient care and in most instances were
discharged on the same day. Although the trend in the cost
analysis suggests a higher overall monetary cost per patient
of approximately 10%, future calculations must take into
account productivity retained by the patient with a shorterlength of stay (0.9 days in the current series) resulting in a
faster return to work/daily activities with a relative absence
of postoperative pain.
CONCLUSION
The choice of percutaneously placed stent-grafts within
the SFA vs open surgical bypass for lower extremity revascu-
larization remains a point of discussion and controversy in
many areas especially if venous conduit for surgical reconstruc-
tion is available. The current study demonstrates through a
prospective randomizedmethod, similar primary and second-
ary patency rates for all TASC II lesions (A-D) in the use of
percutaneously placed stent-grafts vs surgically placed syn-
thetic conduit in the SFAat up to24months.Commonly held
thoughts about a higher rate of limb loss or “loss of options”
for above knee reconstruction in the event of stent-graft failure
are not demonstrated in the current study.
Percutaneous treatment of TASC II C and D lesions
typically have a lower patency than those of TASC II A or B
lesions, however, this does not appear to be the case in our
current study although there is an apparent trend towards
that endpoint. There is not shown to be any significant
difference compared with surgical reconstruction for these
same lesions although our patient cohort is small for this
type of analysis. Additionally, two of four thrombosed
stent-grafts in the higher TASC II categories were 5 mm
devices. The trends presented regarding stent-graft size
suggests that larger diameter devices (5 mm) may have a
better long-term patency with stent-graft reconstruction
unless newer modalities with heparin bonded stent-grafts
or a more prolonged use of antiplatelet agents can improve
the patency of the smaller diameter devices. Again, this data
is only presented as a trend as the current study was not
designed or powered to demonstrate statistical differences
between stent-graft sizes. It is our feeling that for longer
SFA lesions/occlusions (over 10 cm), the stent-graft data
presented herein and among other authors2-13 demon-
strates superior outcomes compared with other currently
available modalities if endovascular treatment is being consid-
ered. There are several recognized limitations to the current
study including a small total patient cohort and a single center
experience, although the data obtained is comparable to pre-
vious reports.2-13 Direct comparison with bare metal nitinol
stents in longer lesions and comparison with current atherec-
tomy devices in longer lesions with a prospective randomized
study would be enlightening.
AUTHOR CONTRIBUTIONS
Conception and design: DG, BT
Analysis and interpretation: DG, KM, GP, SH
Data collection: DG, KM, SH
Writing the article: DG, BT, GP, SH
Critical revision of the article: DG, KM, GP, SH
Final approval of the article: DG, KM, BT, GP, SH
Statistical analysis: KM, SH
Obtained funding: DG
Overall responsibility: DG
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 McQuade et al 115REFERENCES
1. Lammer J, Dake MD, Bleyn J, Katzen B, Cejna M, Piquet P, et al. for the
International Trial Study Group. Peripheral arterial obstruction: prospec-
tive study of treatment with a transluminally placed self-expanding stent-
graft. Radiology 2000;217:95-104.
2. Coats R, Adams Jr J, Humphrey P. SFA revascularization using the
Viabahn Endoprosthesis. Endovasc Today 2006;5:76-8.
3. Railo M, Roth W, Edgren J, Biancari F, Ikonen T, Albäck A, et al.
Preliminary results with endoluminal femoropopliteal thru pass. An-
nales Chirurgiae et Gynacologiae 2001;90:15-8.
4. Jahnke T, Andresen R, Müller-Hülsbeck S, Schafer F, Voshage G,
Heller M, et al. Hemobahn stent-grafts for treatment of femoropopli-
teal arterial obstructions: midterm results of a prospective trial. J Vasc
Intervent Radiol 2003;4:41-51.
5. Turicchia G, Cevolani M, Altini R, Stancanelli V. Midterm results in
PTFE endograft treatment of femoropopliteal occlusive disease. Os-
pedali d’Italia-chirurgia 2003;9:93-6.
6. Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn
endoprosthesis in the treatment of long chronic lesions of the superficial
femoral artery: 6 years of experience. J Endovasc Ther 2006;13:281-90.
7. Hartung O, Otero A, Dubuc M, Boufi M, Barthelemy P, Aissi K, et al.
Efficacy of Hemobahn in the treatment of superficial femoral artery
lesions in patients with acute or critical ischemia: a comparative study
with claudicants. Eur J Vasc Endovasc Surg 2005;30:300-6.
8. Kazemie S, Djelmami-Hani M, Gupta A, Tumulure R, Shalev Y, Allaqa-
band S. One year patency rate of the Viabahn stent-graft for chronic
total occlusion or long high-grade stenosis of the superficial femoral
artery. Am J Cardiol 2006;98:(Suppl S1):235M-6M.
9. Saxon R, Coffman J, Gooding J, Ponec D. Long-term patency of
stent-grafts in the treatment of long-segment femoropopliteal artery
occlusive disease. J Vasc Intervent Radiol 2006;17(Part 2):S2.
10. Bleyn J, Schol F, Vanhandenhove I, Vercaeren P, Marien C. Endovas-
cular reconstruction of the superficial femoral artery. In: Becquemin JP,
Alimi YS, Watelet J, Loisance D, editors. Controversies and updates in
vascular and cardiac surgery. Torino, Italy: Edizioni Minerva Medica
2004:87-91.
11. Zander T, Llorens R, Rostagno R, Zerolo I, Rabellino N, Maynar M.
Hemobahn/Viabahn endograft for long SFA lesions. Long-term follow-
up. J Vasc Intervent Radiol 2006;17(Part 2):S57.
12. Chopra P. Endoluminal femoropopliteal bypass using the Viabahn stent
graft (Endograft): primary and secondary patency in 60 patients (70
limbs) with 3-year follow-up. Abstract presented at the 14th Annual
an endovascular interventionalist, there is a question that arisesAdvanced Interventional Management Symposium (AIMS); Nov
13-16; New York, NY: 2006.
13. Panetta T. Endovascular femoropopliteal bypass with multiple stent
grafts. Endovasc Today 2005;4(Suppl):12-14.
14. Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D.
Randomized comparison of percutaneous Viabahn stent grafts versus
prosthetic femoral-popliteal bypass in the treatment of superficial fem-
oral arterial occlusive disease. J Vasc Surg 2007;45:10-6.
15. Ahn S, Rutheford R, Becker G, Camerota A, Johnston K, McClean G,
et al. Reporting standards for lower extremity arterial endovascular
procedures. J Vasc Surg 1993;17:1103-7.
16. Rutherford R, Baker D, Ernst C, Johnston K, Porter J, Ahn S. Recom-
mended standards for reports dealing with lower extremity ischemia:
revised version. J Vasc Surg 1997;26:517-38.
17. Inter-Society Consensus for the Management of Peripheral Arterial
Disease (TASC II). Norgren L,HiattW,Dormandy J, NehlerM,Harris
K, Fowkes F, et al on behalf of the TASC IIWorkingGroup. J Vasc Surg
2007;45(Suppl):S5-67.
18. Dorrucci V. Treatment of superficial femoral artery occlusive disease.
J Cardiovasc Surg 2004;45:193-201.
19. Bates M, Aburahma A. An update on endovascular therapy of the lower
extremities. J Endovasc Ther 2004;11(Suppl 2):II107-27.
20. Scott E, Biuckians A, Light R, Scibelli C, Milner T, Meier G, et al.
Subintimal angioplasty for the treatment of claudication and critical
limb ischemia: 3-year results. J Vasc Surg 2007;46:959-64.
21. Schlager O, Dick P, Sabeti S, Amighi J, Miekusch W, Minar E, et al.
Long segment SFA stenting-the dark sides: in stent restenosis, clinical
deterioration, and stent fractures. J Endovasc Ther 2005;12:676-84.
22. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Miekusch W, et al.
Balloon angioplasty versus implantation of nitinol stents in the superfi-
cial femoral artery. N Engl J Med 2006;354:1879-88.
23. Krankenberg H, Schluter M, Steinkamp H, Burgelin K, Scheinert D,
Schulte K, et al. Nitinol stent implantation versus percutaneous translumi-
nal angioplasty in superficial femoral artery lesions up to 10 cm in length:
the femoral artery stenting trial (FAST). Circulation 2007;116:285-92.
24. Joels C, York J, Kalbaugh C, Cull D, Langan E, Taylor S. Surgical
implications of early failed endovascular intervention of the superficial
femoral artery. J Vasc Surg 2008;47:562-65.
Submitted Jun 3, 2008; accepted Aug 14, 2008.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSION
Dr Jon Matsumura (Chicago, Ill). I just wanted to congrat-
ulate you for doing such a great randomized trial in just one center
randomizing 100 limbs in about 14 months. When Kedora pre-
sented the 12-month data a couple years ago, I recall there was an
imbalance in the randomization for critical ischemia; there were
more in one group or the other. Could you tell me what the
patency rates were stratified by Rutherford class 5-6 vs the 4s? Or
perhaps you could tell me, of the six amputations, how many of
those were initially presenting with claudication vs RC 5 and 6.
Dr Sidawy. (Washington, D.C.). I would like to have the
senior author, please.
DrGable. You are referring to a slightly higher increase in the
number of patients with critical limb ischemia in the femoral-
popliteal arm. Of those patients that underwent amputation in the
femoral-popliteal arm, only one of those patients was actually
included in the critical ischemia subset. The rest of the RC 5 and six
patients remained patent and did not come to amputation.
DrMatsumura. And were your patency rates similar for your
claudicants as they were for your critical limb ischemia?
DrGable. Patency rates for claudicants vs those with rest pain
or tissue loss were essentially equal and there was no difference.
Dr James McKinsey (New York, NY). As a surgeon as well asfrom all of our interventions; how many of your interventions
changed your surgical option if bypass was eventually required?
Meaning, if you did a femoral-popliteal stent grafting, did you then
negate your ability to perform a fem-pop bypass graft and you
would have to go fem-below knee pop using vein. Did you look at
what bridges you are burning with your endovascular intervention?
Dr McQuade. Six out of ten of the patients in the stent-graft
group that had to go on to subsequent bypass were able to be
bypassed to the above-knee segment refuting the belief that people
who undergo stent-graft placement in the SFA cannot be later
revascularized to the above-knee popliteal segment.
Dr Sidawy. Any addition from the senior author.
Dr Gable. I believe what you are asking is whether or not
when you place a stent graft, are you burning your bridges result-
ing in the inability to do an above-knee fem-pop bypass. That has
not been our experience and that is not what we are seeing. We
tried to address this issue with the slides demonstrating that of the
patients that had thrombosis and had to undergo revascularization
with a bypass procedure, 60% of them were able to be done above
the knee.
Therefore, I do not believe that thrombosis of a stent graft
results in you losing the ability to do a femoral above-knee popli-
teal bypass. Certainly, some of them did result in either below-knee
JOURNAL OF VASCULAR SURGERY
January 2009116 McQuade et alor tibial bypass. There were two patients that we had to do a tibial
artery bypass, but the majority of them were able to stay above the
knee.
Dr Panagiotis Kougias (Houston, Tex). Some people would
argue that in the femoral-popliteal segment Dacron grafts have
yielded inferior results compared with ePTFE. And I notice that
almost two-thirds of your patients had a fem-pop using Dacron
graft. If you could comment on this, please.
Dr Gable. The reason we chose not to mandate either ePTFE
or Dacron is that the purpose of the study was to show the patency
rates and evaluation of the stent graft vs current or most common
prosthetic materials that are available. We are an eight-man group
and half of us use ePTFE routinely and half of us useDacron. There
is some data previously published through numerous studies show-
ing that with ePTFE, when it occludes, you may potentially lose
the ability to do a shorter segment bypass or may potentially lose
some outflow. We have not found those issues to be a big problem
and did not feel that we would want to limit the ability to either
choose Dacron or ePTFE. In addition, most recent meta-analysis
studies of prosthetic fem-pop bypasses do not differentiate the two
types of grafts.
Dr Jamal Hoballah (Iowa City, Iowa). In the stent-graft
group, did you see any negative effect on the profunda femoris
artery, and how would you manage patients who have disease all
the way to the level of the femoral bifurcation?
Dr Gable. We did not see any problems or ill effects on the
profunda artery or any of the collateralized flow from the profunda
artery down the leg. For lesions that came within very close
proximity to the SFA origin, we did not, for the purposes of this
study, land any lesions closer than 1 cm from the origin of the SFA.
Outside of this study, we have come up directly adjacent to the
profunda and have not experienced any problems with either
embolization or recurrent stenosis in that area. Certainly, that is a
concern.
Dr Christopher Kwolek (Boston, Mass). A question about
technique. Do you use any type of debulking procedures prior to
endovascular stent-graft therapy and are you worried about partial
expansion of these endoluminally placed stent grafts? Secondly,
was lesion length or perhaps TASC classification a predictor of
poorer outcome with the stent grafts? Finally, while your initial
results were very good, it seems that your secondary patency rates
were on the low side even for the endovascular. Debulking with
stenting will often report secondary patency approaching 90%. Do
you have any explanation for this?Dr McQuade. To answer the first question in terms of our
technique, we generally use a subintimal dissection technique and
we did not use any reentry catheters. No atherectomy catheters or
debulking devices were used.
The second question involved TASC criteria and lesion
length. Concerning our failures in the stent-graft group, 11 were
actually TASC II-B and then there were 2 TASC II-A, 2 TASC
II-C, and 2 TASC II-D. For our fem-pop group, 10 of the failures
were TASC II-B and 4 of the failures were TASC II-D.We felt that
these larger number of TASC II-B failures in both groups were
secondary to the fact that the majority of our patients had TASC
II-B lesions and that TASC classification had no apparent bearing
on patency in our study. In the stent-graft group, 29 of our
patients were TASC II-B and in the fem-pop group 27 were TASC
II-B.
Dr Gable. As far as the technique for debulking, we did not
use any debulking procedures. Everything was done subintimal.
We did not have to use any reentry catheters, although we do have
that in our armamentarium, but for the purpose of this study and
all of these patients, none of them required any type of reentry
catheter. We did not use laser or mechanical atherectomy. We did
not have any problems obtaining full stent-graft expansion after
deployment.
As far as the secondary patency, the data we are presenting
here is 24-month follow-up. There are only a handful of random-
ized prospective studies published with patency data for bare metal
stent, atherectomy or angioplasty alone. Out of the studies that I
have knowledge of, I do not believe any randomized prospective
study demonstrates any patency data that supersedes what we have
presented and follow-up in most studies that are available are less
than 12 months.
Dr Christos Liapis (Athens, Greece). Regarding the postop
medication, you are giving them either clopidogrel plus aspirin or
Coumadin plus aspirin. If that’s so, for how long and based on
which recommendations you’re using this kind of treatment?
Dr McQuade. The dual antiplatelet therapy was 325 mg
aspirin and 75 mg clopidogrel maintained for 3 months. The
patients who were getting Coumadin were only those patients who
were receiving Coumadin preoperatively. They were maintained
on the pretreatment dose of Coumadin and aspirin 81 mg for 3
months before allowing discontinuation of aspirin. The regimen
was outlined in the study protocol but is not specified elsewhere.
ons through end of interval.
ons through end of interval.
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N at risk at
start of interval
N events
inter
Group: Femoral-popliteal bypass
At procedure (day 0) 50 0 (0
Postoperative (0-31 d) 50 1 (1
1-3 mo (31-137 d) 45 2 (3
3-6 mo (137-228 d) 41 4 (7
6-9 mo (228-320 d) 34 1 (8
9-12 mo (320-410 d) 33 2 (1
12-18 mo (410-593 d) 31 3 (1
18-24 mo (593-730 d) 28 2 (1
Group: Stent-graft
At procedure (day 0) 50 0 (0
Postoperative (0-31 d) 50 1 (1
1-3 mo (31-137 d) 49 6 (7
3-6 mo (137-228 d) 39 2 (9
6-9 mo (228-320 d) 36 4 (1
9-12 mo (320-410 d) 32 0 (1
12-18 mo (410-593 d) 32 3 (1
18-24 mo (593-730 d) 26 1 (1
Log rank P value: P  .716.
aNumber in parenthesis represents cumulative events or censored observati
Table V (online only). Secondary patency
N at risk at
start of interval
N even
during int
Group: Femoral-popliteal bypass
At procedure (day 0) 50 0 (0)
Postoperative (0-31 d) 50 1 (1)
1-3 mo (31-137 d) 45 1 (2)
3-6 mo (137-228 d) 42 3 (5)
6-9 mo (228-320 d) 36 1 (6)
9-12 mo (320-410 d) 35 0 (6)
12-18 mo (410-593 d) 35 2 (8)
18-24 mo (593-730 d) 32 2 (10
Group: Stent-graft
At procedure (day 0) 50 0 (0)
Postoperative (0-31 d) 50 0 (0)
1-3 mo (31-137 d) 50 5 (5)
3-6 mo (137-228 d) 41 2 (7)
6-9 mo (228-320 d) 38 1 (8)
9-12 mo (320-410 d) 37 0 (8)
12-18 mo (410-593 d) 37 3 (11
18-24 mo (593-730 d) 31 1 (12
Log rank P value: P  .695.
aNumber in parenthesis represents cumulative events or censored observatiduring
vala
N censored during
intervala
Percent free from
loss of patency 95% CI
) 0 (0) 1.000 (1.000, 1.000)
) 4 (4) 0.980 (0.866, 0.997)
) 2 (6) 0.935 (0.812, 0.979)
) 3 (9) 0.839 (0.690, 0.920)
) 0 (9) 0.814 (0.661, 0.903)
0) 0 (9) 0.765 (0.606, 0.866)
3) 0 (9) 0.691 (0.526, 0.808)
5) 0 (9) 0.641 (0.476, 0.767)
) 0 (0) 1.000 (1.000, 1.000)
) 0 (0) 0.980 (0.866, 0.997)
) 4 (4) 0.857 (0.722, 0.929)
) 1 (5) 0.813 (0.670, 0.898)
3) 0 (5) 0.722 (0.569, 0.829)
3) 0 (5) 0.722 (0.569, 0.829)
6) 3 (8) 0.654 (0.497, 0.772)
7) 3 (11) 0.627 (0.468, 0.750)ts
ervala
N censored
during intervala
Percent free from
loss of secondary patency 95% CI
0 (0) 1.000 (1.000, 1.000)
4 (4) 0.980 (0.866, 0.997)
2 (6) 0.957 (0.839, 0.989)
3 (9) 0.885 (0.745, 0.951)
0 (9) 0.861 (0.715, 0.935)
0 (9) 0.861 (0.715, 0.935)
1 (10) 0.811 (0.657, 0.901)
) 0 (10) 0.761 (0.600, 0.864)
0 (0) 1.000 (1.000, 1.000)
0 (0) 1.000 (1.000, 1.000)
4 (4) 0.899 (0.773, 0.957)
1 (5) 0.855 (0.719, 0.928)
0 (5) 0.832 (0.692, 0.913)
0 (5) 0.832 (0.692, 0.913)
) 3 (8) 0.764 (0.614, 0.862)
) 3 (11) 0.738 (0.583, 0.843)
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N at risk at start
of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: Femoral-popliteal bypass TASC II A-B
At procedure (day 0) 35 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 35 1 (1) 3 (3) 0.971 (0.814, 0.996)
1-3 mo (31-137 d) 31 1 (2) 1 (4) 0.940 (0.781, 0.985)
3-6 mo (137-228 d) 29 2 (4) 2 (6) 0.873 (0.694, 0.950)
6-9 mo (228-320 d) 25 1 (5) 0 (6) 0.838 (0.652, 0.929)
9-12 mo (320-410 d) 24 2 (7) 0 (6) 0.768 (0.573, 0.883)
12-18 mo (410-593 d) 22 2 (9) 0 (6) 0.698 (0.499, 0.831)
18-24 mo (593-730 d) 20 2 (11) 0 (6) 0.628 (0.429, 0.775)
Group: Femoral-popliteal bypass TASC II
C-D
At procedure (day 0) 15 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 15 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 14 1 (1) 1 (2) 0.923 (0.566, 0.989)
3-6 mo (137-228 d) 12 2 (3) 1 (3) 0.755 (0.416, 0.914)
6-9 mo (228-320 d) 9 0 (3) 0 (3) 0.755 (0.416, 0.914)
9-12 mo (320-410 d) 9 0 (3) 0 (3) 0.755 (0.416, 0.914)
12-18 mo (410-593 d) 9 1 (4) 0 (3) 0.671 (0.342, 0.862)
18-24 mo (593-730 d) 8 0 (4) 0 (3) 0.671 (0.342, 0.862)
Group: Stent-graft TASC II A-B
At procedure (day 0) 39 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 39 1 (1) 0 (0) 0.974 (0.832, 0.996)
1-3 mo (31-137 d) 38 4 (5) 3 (3) 0.869 (0.714, 0.944)
3-6 mo (137-228 d) 31 2 (7) 1 (4) 0.813 (0.647, 0.907)
6-9 mo (228-320 d) 28 4 (11) 0 (4) 0.697 (0.519, 0.820)
9-12 mo (320-410 d) 24 0 (11) 0 (4) 0.697 (0.519, 0.820)
12-18 mo (410-593 d) 24 2 (13) 1 (5) 0.639 (0.459, 0.773)
18-24 mo (593-730 d) 21 0 (13) 1 (6) 0.639 (0.459, 0.773)
Group: Stent-graft TASC II C-D
At procedure (day 0) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 11 2 (2) 1 (1) 0.818 (0.447, 0.951)
3-6 mo (137-228 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
6-9 mo (228-320 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
9-12 mo (320-410 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
12-18 mo (410-593 d) 8 1 (3) 2 (3) 0.716 (0.350, 0.899)
18-24 mo (593-730 d) 5 1 (4) 2 (5) 0.477 (0.086, 0.800)
TASC, TransAtlantic InterSociety Consensus.
Log rank P value: P  .978.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: Femoral-popliteal bypass TASC II A-B
At procedure (day 0) 35 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 35 1 (1) 3 (3) 0.971 (0.814, 0.996)
1-3 mo (31-137 d) 31 0 (1) 1 (4) 0.971 (0.814, 0.996)
3-6 mo (137-228 d) 30 2 (3) 2 (6) 0.904 (0.730, 0.968)
6-9 mo (228-320 d) 26 1 (4) 0 (6) 0.869 (0.687, 0.949)
9-12 mo (320-410 d) 25 0 (4) 0 (6) 0.869 (0.687, 0.949)
12-18 mo (410-593 d) 25 1 (5) 1 (7) 0.835 (0.646, 0.928)
18-24 mo (593-730 d) 23 2 (7) 0 (7) 0.762 (0.563, 0.879)
Group: Femoral-popliteal bypass TASC II
C-D
At procedure (day 0) 15 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 15 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 14 1 (1) 1 (2) 0.923 (0.566, 0.989)
3-6 mo (137-228 d) 12 1 (2) 1 (3) 0.839 (0.494, 0.957)
6-9 mo (228-320 d) 10 0 (2) 0 (3) 0.839 (0.494, 0.957)
9-12 mo (320-410 d) 10 0 (2) 0 (3) 0.839 (0.494, 0.957)
12-18 mo (410-593 d) 10 1 (3) 0 (3) 0.755 (0.416, 0.914)
18-24 mo (593-730 d) 9 0 (3) 0 (3) 0.755 (0.416, 0.914)
Group: Stent-graft TASC II A-B
At procedure (day 0) 39 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 39 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 39 3 (3) 3 (3) 0.923 (0.780, 0.975)
3-6 mo (137-228 d) 33 2 (5) 1 (4) 0.867 (0.709, 0.943)
6-9 mo (228-320 d) 30 1 (6) 0 (4) 0.838 (0.674, 0.924)
9-12 mo (320-410 d) 29 0 (6) 0 (4) 0.838 (0.674, 0.924)
12-18 mo (410-593 d) 29 2 (8) 1 (5) 0.780 (0.608, 0.884)
18-24 mo (593-730 d) 26 0 (8) 1 (6) 0.780 (0.608, 0.884)
Group: Stent-graft TASC II C-D
At procedure (day 0) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 11 2 (2) 1 (1) 0.818 (0.447, 0.951)
3-6 mo (137-228 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
6-9 mo (228-320 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
9-12 mo (320-410 d) 8 0 (2) 0 (1) 0.818 (0.447, 0.951)
12-18 mo (410-593 d) 8 1 (3) 2 (3) 0.716 (0.350, 0.899)
18-24 mo (593-730 d) 5 1 (4) 2 (5) 0.477 (0.086, 0.800)
TASC, TransAtlantic InterSociety Consensus.
Log rank P value: P  .653.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
amputation 95% CI
Group: Femoral-popliteal bypass
At procedure (day 0) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 50 2 (2) 3 (3) 0.960 (0.849, 0.990)
1-3 mo (31-137 d) 45 1 (3) 1 (4) 0.938 (0.820, 0.980)
3-6 mo (137-228 d) 43 1 (4) 5 (9) 0.914 (0.786, 0.967)
6-9 mo (228-320 d) 37 1 (5) 0 (9) 0.889 (0.753, 0.953)
9-12 mo (320-410 d) 36 0 (5) 0 (9) 0.889 (0.753, 0.953)
12-18 mo (410-593 d) 36 0 (5) 1 (10) 0.889 (0.753, 0.953)
18-24 mo (593-730 d) 35 0 (5) 0 (10) 0.889 (0.753, 0.953)
Group: Stent-graft
At procedure (day 0) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 50 1 (1) 5 (5) 0.980 (0.866, 0.997)
3-6 mo (137-228 d) 44 0 (1) 1 (6) 0.980 (0.866, 0.997)
6-9 mo (228-320 d) 43 0 (1) 0 (6) 0.980 (0.866, 0.997)
9-12 mo (320-410 d) 43 0 (1) 0 (6) 0.980 (0.866, 0.997)
12-18 mo (410-593 d) 43 0 (1) 3 (9) 0.980 (0.866, 0.997)
18-24 mo (593-730 d) 40 0 (1) 4 (13) 0.980 (0.866, 0.997)Log rank P value: P  .081.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.Table XI (online only). Primary patency by stent-graft size
N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: Femoral-popliteal bypass
At procedure (day 0) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
1-3 mo (31-137 d) 45 2 (3) 2 (6) 0.935 (0.812, 0.979)
3-6 mo (137-228 d) 41 4 (7) 3 (9) 0.839 (0.690, 0.920)
6-9 mo (228-320 d) 34 1 (8) 0 (9) 0.814 (0.661, 0.903)
9-12 mo (320-410 d) 33 2 (10) 0 (9) 0.765 (0.606, 0.866)
12-18 mo (410-593 d) 31 3 (13) 0 (9) 0.691 (0.526, 0.808)
18-24 mo (593-730 d) 28 2 (15) 0 (9) 0.641 (0.476, 0.767)
Group: Stent-graft 5 cm
At procedure (day 0) 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 21 1 (1) 0 (0) 0.952 (0.707, 0.993)
1-3 mo (31-137 d) 20 4 (5) 1 (1) 0.762 (0.519, 0.893)
3-6 mo (137-228 d) 15 1 (6) 1 (2) 0.711 (0.466, 0.859)
6-9 mo (228-320 d) 13 2 (8) 0 (2) 0.602 (0.357, 0.779)
9-12 mo (320-410 d) 11 0 (8) 0 (2) 0.602 (0.357, 0.779)
12-18 mo (410-593 d) 11 0 (8) 2 (4) 0.602 (0.357, 0.779)
18-24 mo (593-730 d) 9 1 (9) 0 (4) 0.535 (0.290, 0.729)
Group: Stent-graft 6-7 cm
At procedure (day 0) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 29 2 (2) 3 (3) 0.924 (0.730, 0.981)
3-6 mo (137-228 d) 24 1 (3) 0 (3) 0.886 (0.687, 0.962)
6-9 mo (228-320 d) 23 2 (5) 0 (3) 0.809 (0.600, 0.916)
9-12 mo (320-410 d) 21 0 (5) 0 (3) 0.809 (0.600, 0.916)
12-18 mo (410-593 d) 21 3 (8) 1 (4) 0.691 (0.476, 0.832)
18-24 mo (593-730 d) 17 0 (8) 3 (7) 0.691 (0.476, 0.832)
Log rank P value: P  .356.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of secondary patency 95% CI
Group: Femoral-popliteal bypass
At procedure (day 0) 50 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 50 1 (1) 4 (4) 0.980 (0.866, 0.997)
1-3 mo (31-137 d) 45 1 (2) 2 (6) 0.957 (0.839, 0.989)
3-6 mo (137-228 d) 42 3 (5) 3 (9) 0.885 (0.745, 0.951)
6-9 mo (228-320 d) 36 1 (6) 0 (9) 0.861 (0.715, 0.935)
9-12 mo (320-410 d) 35 0 (6) 0 (9) 0.861 (0.715, 0.935)
12-18 mo (410-593 d) 35 2 (8) 1 (10) 0.811 (0.657, 0.901)
18-24 mo (593-730 d) 32 2 (10) 0 (10) 0.761 (0.600, 0.864)
Group: Stent-graft 5 cm
At procedure (day 0) 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 21 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 21 4 (4) 1 (1) 0.810 (0.569, 0.924)
3-6 mo (137-228 d) 16 1 (5) 1 (2) 0.759 (0.514, 0.892)
6-9 mo (228-320 d) 14 0 (5) 0 (2) 0.759 (0.514, 0.892)
9-12 mo (320-410 d) 14 0 (5) 0 (2) 0.759 (0.514, 0.892)
12-18 mo (410-593 d) 14 0 (5) 2 (4) 0.759 (0.514, 0.892)
18-24 mo (593-730 d) 12 1 (6) 0 (4) 0.696 (0.439, 0.852)
Group: Stent-graft 6-7 cm
At procedure (day 0) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 29 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 29 1 (1) 3 (3) 0.963 (0.765, 0.995)
3-6 mo (137-228 d) 25 1 (2) 0 (3) 0.924 (0.730, 0.981)
6-9 mo (228-320 d) 24 1 (3) 0 (3) 0.886 (0.687, 0.962)
9-12 mo (320-410 d) 23 0 (3) 0 (3) 0.886 (0.687, 0.962)
12-18 mo (410-593 d) 23 3 (6) 1 (4) 0.768 (0.555, 0.889)
18-24 mo (593-730 d) 19 0 (6) 3 (7) 0.768 (0.555, 0.889)Log rank P value: P  .670.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: 5 mm stent-graft TASC II A
At procedure (day 0) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 7 1 (1) 0 (0) 0.857 (0.334, 0.979)
9-12 mo (320-410 d) 6 0 (1) 0 (0) 0.857 (0.334, 0.979)
12-18 mo (410-593 d) 6 0 (1) 0 (0) 0.857 (0.334, 0.979)
18-24 mo (593-730 d) 6 0 (1) 0 (0) 0.857 (0.334, 0.979)
Group: 5 mm stent-graft TASC II B
At procedure (day 0) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 11 1 (1) 0 (0) 0.909 (0.508, 0.987)
1-3 mo (31-137 d) 10 3 (4) 1 (1) 0.636 (0.297, 0.845)
3-6 mo (137-228 d) 6 1 (5) 1 (2) 0.530 (0.209, 0.773)
6-9 mo (228-320 d) 4 1 (6) 0 (2) 0.398 (0.110, 0.680)
9-12 mo (320-410 d) 3 0 (6) 0 (2) 0.398 (0.110, 0.680)
12-18 mo (410-593 d) 3 0 (6) 1 (3) 0.398 (0.110, 0.680)
18-24 mo (593-730 d) 2 0 (6) 0 (3) 0.398 (0.110, 0.680)
Group: 5 mm stent-graft TASC II C
At procedure (day 0) 2 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 2 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 2 1 (1) 0 (0) 0.500 (0.006, 0.910)
3-6 mo (137-228 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
6-9 mo (228-320 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
9-12 mo (320-410 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
12-18 mo (410-593 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
18-24 mo (593-730 d) 1 1 (2) 0 (0) 0.000 (0.006, 0.910)
Group: 5 mm stent-graft TASC II D
At procedure (day 0) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 1 0 (0) 1 (1) .
18-24 mo (593-730 d) 0 0 (0) 0 (1) .
Group: 6-7 mm stent-graft TASC II A
At procedure (day 0) 3 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 3 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 3 0 (0) 1 (1) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 2 1 (1) 0 (1) 0.500 (0.006, 0.910)
18-24 mo (593-730 d) 1 0 (1) 0 (1) 0.500 (0.006, 0.910)
Group: 6-7 mm stent-graft TASC II B
At procedure (day 0) 18 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 18 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 18 1 (1) 1 (1) 0.941 (0.650, 0.991)
3-6 mo (137-228 d) 16 1 (2) 0 (1) 0.882 (0.606, 0.969)
6-9 mo (228-320 d) 15 2 (4) 0 (1) 0.765 (0.488, 0.904)
9-12 mo (320-410 d) 13 0 (4) 0 (1) 0.765 (0.488, 0.904)
12-18 mo (410-593 d) 13 1 (5) 0 (1) 0.706 (0.431, 0.866)
18-24 mo (593-730 d) 12 0 (5) 1 (2) 0.706 (0.431, 0.866)
Group: 6-7 mm stent-graft TASC II C
At procedure (day 0) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 4 0 (0) 2 (2) 1.000 (1.000, 1.000)
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: 6-7 mm stent-graft TASC II D
At procedure (day 0) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 1 (1) 1 (1) 0.750 (0.128, 0.961)
3-6 mo (137-228 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
6-9 mo (228-320 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
9-12 mo (320-410 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
12-18 mo (410-593 d) 2 1 (2) 1 (2) .
18-24 mo (593-730 d) 0 0 (2) 0 (2) .
Group: Femoral-popliteal bypass TASC II A
At procedure (day 0) 8 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 8 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 7 0 (0) 1 (2) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 6 0 (0) 1 (3) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
Group: Femoral-popliteal bypass TASC II B
At procedure (day 0) 27 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 27 1 (1) 2 (2) 0.963 (0.765, 0.995)
1-3 mo (31-137 d) 24 1 (2) 0 (2) 0.923 (0.725, 0.980)
3-6 mo (137-228 d) 23 2 (4) 1 (3) 0.841 (0.629, 0.937)
6-9 mo (228-320 d) 20 1 (5) 0 (3) 0.799 (0.581, 0.911)
9-12 mo (320-410 d) 19 2 (7) 0 (3) 0.715 (0.492, 0.853)
12-18 mo (410-593 d) 17 2 (9) 0 (3) 0.631 (0.409, 0.788)
18-24 mo (593-730 d) 15 2 (11) 0 (3) 0.546 (0.332, 0.718)
Group: Femoral-popliteal bypass TASC II C
At procedure (day 0) 5 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 5 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
Group: Femoral-popliteal bypass TASC II D
At procedure (day 0) 10 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 10 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 10 1 (1) 1 (1) 0.889 (0.433, 0.984)
3-6 mo (137-228 d) 8 2 (3) 1 (2) 0.635 (0.238, 0.866)
6-9 mo (228-320 d) 5 0 (3) 0 (2) 0.635 (0.238, 0.866)
9-12 mo (320-410 d) 5 0 (3) 0 (2) 0.635 (0.238, 0.866)
12-18 mo (410-593 d) 5 1 (4) 0 (2) 0.508 (0.157, 0.781)
18-24 mo (593-730 d) 4 0 (4) 0 (2) 0.508 (0.157, 0.781)TASC, TransAtlantic InterSociety Consensus.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
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N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: 5 mm stent-graft TASC II A
At procedure (day 0) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 7 0 (0) 0 (0) 1.000 (1.000, 1.000)
Group: 5 mm stent-graft TASC II B
At procedure (day 0) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 11 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 11 3 (3) 1 (1) 0.727 (0.371, 0.903)
3-6 mo (137-228 d) 7 1 (4) 1 (2) 0.623 (0.277, 0.840)
6-9 mo (228-320 d) 5 0 (4) 0 (2) 0.623 (0.277, 0.840)
9-12 mo (320-410 d) 5 0 (4) 0 (2) 0.623 (0.277, 0.840)
12-18 mo (410-593 d) 5 0 (4) 1 (3) 0.623 (0.277, 0.840)
18-24 mo (593-730 d) 4 0 (4) 0 (3) 0.623 (0.277, 0.840)
Group: 5 mm stent-graft TASC II C
At procedure (day 0) 2 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 2 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 2 1 (1) 0 (0) 0.500 (0.006, 0.910)
3-6 mo (137-228 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
6-9 mo (228-320 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
9-12 mo (320-410 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
12-18 mo (410-593 d) 1 0 (1) 0 (0) 0.500 (0.006, 0.910)
18-24 mo (593-730 d) 1 1 (2) 0 (0) 0.000 (0.006, 0.910)
Group: 5 mm stent-graft TASC II D
At procedure (day 0) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 1 0 (0) 0 (0) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 1 0 (0) 1 (1) .
18-24 mo (593-730 d) 0 0 (0) 0 (1) .
Group: 6-7 mm stent-graft TASC II A
At procedure (day 0) 3 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 3 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 3 0 (0) 1 (1) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 2 0 (0) 0 (1) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 2 1 (1) 0 (1) 0.500 (0.006, 0.910)
18-24 mo (593-730 d) 1 0 (1) 0 (1) 0.500 (0.006, 0.910)
Group: 6-7 mm stent-graft TASC II B
At procedure (day 0) 18 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 18 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 18 0 (0) 1 (1) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 17 1 (1) 0 (1) 0.941 (0.650, 0.991)
6-9 mo (228-320 d) 16 1 (2) 0 (1) 0.882 (0.606, 0.969)
9-12 mo (320-410 d) 15 0 (2) 0 (1) 0.882 (0.606, 0.969)
12-18 mo (410-593 d) 15 1 (3) 0 (1) 0.824 (0.547, 0.939)
18-24 mo (593-730 d) 14 0 (3) 1 (2) 0.824 (0.547, 0.939)
Group: 6-7 mm stent-graft TASC II C
At procedure (day 0) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 4 0 (0) 2 (2) 1.000 (1.000, 1.000)
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 McQuade et al 116.e9Table XIV. Continued
N at risk at
start of interval
N events
during intervala
N censored
during intervala
Percent free from
loss of patency 95% CI
Group: 6-7 mm stent-graft TASC II D
At procedure (day 0) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 4 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 1 (1) 1 (1) 0.750 (0.128, 0.961)
3-6 mo (137-228 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
6-9 mo (228-320 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
9-12 mo (320-410 d) 2 0 (1) 0 (1) 0.750 (0.128, 0.961)
12-18 mo (410-593 d) 2 1 (2) 1 (2) .
18-24 mo (593-730 d) 0 0 (2) 0 (2) .
Group: Femoral-popliteal bypass TASC II A
At procedure (day 0) 8 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 8 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 7 0 (0) 1 (2) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 6 0 (0) 1 (3) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 5 0 (0) 0 (3) 1.000 (1.000, 1.000)
Group: Femoral-popliteal bypass TASC II B
At procedure (day 0) 27 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 27 1 (1) 2 (2) 0.963 (0.765, 0.995)
1-3 mo (31-137 d) 24 0 (1) 0 (2) 0.963 (0.765, 0.995)
3-6 mo (137-228 d) 24 2 (3) 1 (3) 0.881 (0.674, 0.960)
6-9 mo (228-320 d) 21 1 (4) 0 (3) 0.839 (0.625, 0.936)
9-12 mo (320-410 d) 20 0 (4) 0 (3) 0.839 (0.625, 0.936)
12-18 mo (410-593 d) 20 1 (5) 1 (4) 0.797 (0.578, 0.910)
18-24 mo (593-730 d) 18 2 (7) 0 (4) 0.708 (0.482, 0.850)
Group: Femoral-popliteal bypass TASC II C
At procedure (day 0) 5 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 5 0 (0) 1 (1) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
3-6 mo (137-228 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
6-9 mo (228-320 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
9-12 mo (320-410 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
12-18 mo (410-593 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
18-24 mo (593-730 d) 4 0 (0) 0 (1) 1.000 (1.000, 1.000)
Group: Femoral-popliteal bypass TASC II D
At procedure (day 0) 10 0 (0) 0 (0) 1.000 (1.000, 1.000)
Postoperative (0-31 d) 10 0 (0) 0 (0) 1.000 (1.000, 1.000)
1-3 mo (31-137 d) 10 1 (1) 1 (1) 0.889 (0.433, 0.984)
3-6 mo (137-228 d) 8 1 (2) 1 (2) 0.762 (0.332, 0.935)
6-9 mo (228-320 d) 6 0 (2) 0 (2) 0.762 (0.332, 0.935)
9-12 mo (320-410 d) 6 0 (2) 0 (2) 0.762 (0.332, 0.935)
12-18 mo (410-593 d) 6 1 (3) 0 (2) 0.635 (0.238, 0.866)
18-24 mo (593-730 d) 5 0 (3) 0 (2) 0.635 (0.238, 0.866)TASC, TransAtlantic InterSociety Consensus.
aNumber in parenthesis represents cumulative events or censored observations through end of interval.
